- 104 Downloads
Imidapril (Tanatril™), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP).
In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension.
The active metabolite of imidapril is imidaprilat, which inhibits the conversion of angiotensin I to angiotensin II. Lowering of plasma and tissue angiotensin II levels results in peripheral vasodilation, reduced systemic BP, renoprotective effects in patients with type 1 diabetes, and decreased renal sodium and water retention.
After multidose oral administration in patients with hypertension, steady-state maximum plasma concentrations of imidapril (≈30 ng/mL) and imidaprilat (≈20 ng/mL) are achieved in a median time of 2 and 5 hours. In healthy men 25.5% of a single dose of imidapril 10mg was excreted in the urine within 24 hours. Elimination occurs primarily through excretion in the urine (≈40%) and faeces (≈50%); after oral administration in healthy volunteers, the terminal elimination half-life of imidaprilat is ≈24 hours.
In randomised controlled trials, oral imidapril was effective in the treatment of adults with mild to moderate essential hypertension. In short-term (2- and 4-week) dose-finding trials, imidapril dosages of 10–40 mg/day were significantly more effective than placebo, inducing 11–15mm Hg reductions in sitting diastolic BP (sDBP; primary endpoint). In comparative 12- and 24-week trials, imidapril 5–20 mg/day induced reductions in mean sDBP of 10–15mm Hg that did not differ significantly from those induced by hydrochlorothiazide 12.5–50 mg/day or captopril 50–100 mg/day (primary endpoint), nor those induced by enalapril 5–10 mg/day or nifedipine sustained release (SR) 40–80 mg/day (secondary endpoint). In addition, reductions in sDBP and sitting systolic BP (co-primary endpoints) with imidapril did not differ from those induced by candesartan 4–16 mg/day. Favourable reductions in sDBP were maintained during 6-month and 52-week noncomparative trials.
In patients with type 1 diabetes, the urinary albumin excretion rate (a marker of nephropathy) increased by 72% in placebo recipients, but declined by 41% in imidapril 5 mg/day and by 6% in captopril 37.5 mg/day recipients during a mean treatment period of 1.5 years.
In patients with CHF, mean total exercise time increased from baseline in imidapril 2.5–10 mg/day recipients in a dose-related manner after 12-weeks of treatment; a 9.7% increase with imidapril 10 mg/day was significantly greater than the change with placebo (+0.7%).
Overall, imidapril was relatively well tolerated, with an incidence of adverse events in pooled analyses of data from clinical trials and post-marketing surveillance (n = 6632) of 6.6%. The most commonly reported adverse events were cough, hypotension, dizziness and pharyngeal discomfort. During 2- and 4-week trials, the overall incidence of adverse events was 26% and 40% in recipients of imidapril 2.5–40 mg/day compared with 35% and 37% in placebo recipients. In comparative trials, the incidence of treatment-related adverse events in imidapril versus enalapril recipients in two 12-week trials were 5.6% versus 12.2% and 12.0% versus 14.1%; in other 12-week trials treatment-related adverse events were observed in 24.2% of imidapril versus 41.7% of nifedipine SR, and 20.7% of imidapril versus 46.4% of captopril recipients, while the overall incidence of adverse events in imidapril versus candesartan recipients was 11.7% versus 16.1%. The incidences of adverse events in a 24-week trial were 46.0% with imidapril and 52.8% with hydrochlorothiazide. In longer-term trials, adverse events were reported by 61.6% of imidapril recipients in the 52-week trial; however, only 1.7% of imidapril recipients in a 6-month field trial experienced adverse events considered related to ACE inhibitor treatment.
In prospective investigations in hypertensive patients, switching to imidapril did not reduce the incidence of cough (a class effect of ACE inhibitors) in a small open-label trial in hypertensive patients already experiencing ACE-inhibitor induced cough; however, in a large crossover trial, the incidence of cough with imidapril (15.2%) was less than half that with enalapril (38.6%). In addition, cough disappeared in 52.9% of enalapril recipients switched to imidapril, and in patients without cough during imidapril treatment, switching to enalapril induced cough in 20.9%. In contrast, in patients without cough during initial enalapril treatment, only 0.9% developed cough during subsequent imidapril treatment. In a second large, double-blind crossover trial, the incidence of cough was significantly lower in imidapril than benazepril recipients.
- 2.World Health Organization. The World Health Report 2002: reducing risks, promoting healthy life [online]. Available from URL: http://www.who.int/whr/2002/en/index.html [Accessed 2006 Jul 28]
- 4.Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology [online]. Available from URL: http://escol.es-cardio.org/ [Accessed 2006 Aug 9]
- 5.Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 Sep 20; 112 (12): el54–235CrossRefGoogle Scholar
- 7.TANATRIL® tablets 2.5 and 5mg (imidapril hydrochloride); Japanese prescribing information (English version). Osaka: Tanabe Sciyaku Co. Ltd, 2005 JunGoogle Scholar
- 8.Dews I, VandenBurg M. A 24-week dose-titration study of the angiotensin-converting enzyme inhibitor imidapril in the treatment of mild-to-moderate essential hypertension in the elderly. J Int Med Res 2001 Mar–Apr, 100-7Google Scholar
- 9.Data on File. Tanabe Sciyaku Co. Ltd, 2007Google Scholar
- 10.Summary of product characteristics: Tanatril 5 mg tablet. Tanabe Europe N.V., 2002 Nov 11Google Scholar
- 13.Kubo M, Kato J, Ochiai T, et al. Pharmacological studies on (4S)-1 -methyl-3- (2s)-2-[n-( (1s)-l -ethoxycarbonyl-3-phenyl-propyl)amino]propionyl-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: I. ACE inhibitory and antihypertensive activities. Jpn J Pharmacol 1990; 53: 201–10PubMedCrossRefGoogle Scholar
- 14.Kubo M, Ochiai T, Kato J, et al. Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). Jpn J Pharmacol 1991; 57: 517–26PubMedCrossRefGoogle Scholar
- 30.Higashi Y, Sasaki S, Nakagawa K, et al. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001 Mar 1; 37 (3): 863–70PubMedCrossRefGoogle Scholar
- 32.Higashi Y, Sasaki S, Nakagawa K, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000 Feb; 35 (2): 284–91PubMedCrossRefGoogle Scholar
- 38.Yoshitomi Y, Kojima S, Yano M, et al. Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency. Am Heart J 2000 Dec; 140 (6): E27 (1–7)CrossRefGoogle Scholar
- 40.Tokudome M, Uno T, Sato Y. Effects of imidapril treatment on insulin resistance in diabetic patients [in Japanese]. J Jpn Diabetes Soc 2003; 46 (8): 685–8Google Scholar
- 46.MacGregor GA. Expert report on the clinical documentation. Tanabe Sciyaku Co. Ltd, 1996. (Data on file)Google Scholar
- 48.Takahashi M, Minatoguchi S, Nishigaki K, et al. Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: an evaluation using a novel indicator of burden on the left ventricle. Hypertens Res 2006 Feb; 29 (2): 89–94PubMedCrossRefGoogle Scholar
- 50.Katayama S, Kikkawa R, Isogai S, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM) [published erratum appears in Diabetes Res Clin Pract 2002 Jul; 57 (1): 71]. Diabetes Res Clin Pract 2002 Feb; 55: 113–21PubMedCrossRefGoogle Scholar
- 53.Hirota Y, Kawamura K, Ooyagi A. Phase I study of TA-6366 (I): single oral administration [in Japanese]. J Clin Ther Med 1992; 8: 507–22Google Scholar
- 55.Palma Gámiz JL, Pêgo M, Contreras EM, et al. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolera-bility of imidapril and candesartan in adult patients with mild to moderate essential hypertension: The Iberian Multicenter Imidapril study on hypertension (IMISH). Clin Ther 2006 Dec; 28 (12): 2040–51PubMedCrossRefGoogle Scholar
- 58.Liu G. Comparative study of hypotensive efficacy and the cough occurrence of imidapril versus benazepril [in Chinese]. Chin J Cardiol 2004 Apr; 32 (4): 304–7Google Scholar
- 61.Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. National High Blood Pressure Education Program Coordinating Committee. JAMA 2003 May 21; 289 (19): 2560–72PubMedCrossRefGoogle Scholar
- 63.Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755–62PubMedCrossRefGoogle Scholar
- 68.2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee [published erratum appears in J Hypertens 2003 Nov; 21 (11): 2203–4 and J Hypertens 2004 Feb; 22 (2): 435]. J Hypertens 2003 Jun; 21 (6): 1011–53CrossRefGoogle Scholar
- 71.Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000 Dec 9; 356 (9246): 1955–64PubMedCrossRefGoogle Scholar
- 73.Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165 (12): 1410–9PubMedCrossRefGoogle Scholar
- 83.National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care. Partial update. London: Royal College of Physicians, 2006 [online]. Available from URL: http://www.nice.org.uk/download.aspx?o=CG034fullguideline [Accessed 2006 Aug10]Google Scholar
- 85.National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Aug 15]